Cargando…

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors

The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fus...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishima, Saori, Naito, Yoichi, Akagi, Kiwamu, Hayashi, Naomi, Hirasawa, Akira, Hishiki, Tomoro, Igarashi, Ataru, Ikeda, Masafumi, Kadowaki, Shigenori, Kajiyama, Hiroaki, Kato, Motohiro, Kenmotsu, Hirotsugu, Kodera, Yasuhiro, Komine, Keigo, Koyama, Takafumi, Maeda, Osamu, Miyachi, Mitsuru, Nishihara, Hiroshi, Nishiyama, Hiroyuki, Ohga, Shouichi, Okamoto, Wataru, Oki, Eiji, Ono, Shigeru, Sanada, Masashi, Sekine, Ikuo, Takano, Tadao, Tao, Kayoko, Terashima, Keita, Tsuchihara, Katsuya, Yatabe, Yasushi, Yoshino, Takayuki, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390617/
https://www.ncbi.nlm.nih.gov/pubmed/37300720
http://dx.doi.org/10.1007/s10147-023-02360-8
_version_ 1785082516744437760
author Mishima, Saori
Naito, Yoichi
Akagi, Kiwamu
Hayashi, Naomi
Hirasawa, Akira
Hishiki, Tomoro
Igarashi, Ataru
Ikeda, Masafumi
Kadowaki, Shigenori
Kajiyama, Hiroaki
Kato, Motohiro
Kenmotsu, Hirotsugu
Kodera, Yasuhiro
Komine, Keigo
Koyama, Takafumi
Maeda, Osamu
Miyachi, Mitsuru
Nishihara, Hiroshi
Nishiyama, Hiroyuki
Ohga, Shouichi
Okamoto, Wataru
Oki, Eiji
Ono, Shigeru
Sanada, Masashi
Sekine, Ikuo
Takano, Tadao
Tao, Kayoko
Terashima, Keita
Tsuchihara, Katsuya
Yatabe, Yasushi
Yoshino, Takayuki
Baba, Eishi
author_facet Mishima, Saori
Naito, Yoichi
Akagi, Kiwamu
Hayashi, Naomi
Hirasawa, Akira
Hishiki, Tomoro
Igarashi, Ataru
Ikeda, Masafumi
Kadowaki, Shigenori
Kajiyama, Hiroaki
Kato, Motohiro
Kenmotsu, Hirotsugu
Kodera, Yasuhiro
Komine, Keigo
Koyama, Takafumi
Maeda, Osamu
Miyachi, Mitsuru
Nishihara, Hiroshi
Nishiyama, Hiroyuki
Ohga, Shouichi
Okamoto, Wataru
Oki, Eiji
Ono, Shigeru
Sanada, Masashi
Sekine, Ikuo
Takano, Tadao
Tao, Kayoko
Terashima, Keita
Tsuchihara, Katsuya
Yatabe, Yasushi
Yoshino, Takayuki
Baba, Eishi
author_sort Mishima, Saori
collection PubMed
description The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.
format Online
Article
Text
id pubmed-10390617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-103906172023-08-02 Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors Mishima, Saori Naito, Yoichi Akagi, Kiwamu Hayashi, Naomi Hirasawa, Akira Hishiki, Tomoro Igarashi, Ataru Ikeda, Masafumi Kadowaki, Shigenori Kajiyama, Hiroaki Kato, Motohiro Kenmotsu, Hirotsugu Kodera, Yasuhiro Komine, Keigo Koyama, Takafumi Maeda, Osamu Miyachi, Mitsuru Nishihara, Hiroshi Nishiyama, Hiroyuki Ohga, Shouichi Okamoto, Wataru Oki, Eiji Ono, Shigeru Sanada, Masashi Sekine, Ikuo Takano, Tadao Tao, Kayoko Terashima, Keita Tsuchihara, Katsuya Yatabe, Yasushi Yoshino, Takayuki Baba, Eishi Int J Clin Oncol Special Article The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy. Springer Nature Singapore 2023-06-10 2023 /pmc/articles/PMC10390617/ /pubmed/37300720 http://dx.doi.org/10.1007/s10147-023-02360-8 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Special Article
Mishima, Saori
Naito, Yoichi
Akagi, Kiwamu
Hayashi, Naomi
Hirasawa, Akira
Hishiki, Tomoro
Igarashi, Ataru
Ikeda, Masafumi
Kadowaki, Shigenori
Kajiyama, Hiroaki
Kato, Motohiro
Kenmotsu, Hirotsugu
Kodera, Yasuhiro
Komine, Keigo
Koyama, Takafumi
Maeda, Osamu
Miyachi, Mitsuru
Nishihara, Hiroshi
Nishiyama, Hiroyuki
Ohga, Shouichi
Okamoto, Wataru
Oki, Eiji
Ono, Shigeru
Sanada, Masashi
Sekine, Ikuo
Takano, Tadao
Tao, Kayoko
Terashima, Keita
Tsuchihara, Katsuya
Yatabe, Yasushi
Yoshino, Takayuki
Baba, Eishi
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title_full Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title_fullStr Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title_full_unstemmed Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title_short Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
title_sort japanese society of medical oncology/japan society of clinical oncology/japanese society of pediatric hematology/oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390617/
https://www.ncbi.nlm.nih.gov/pubmed/37300720
http://dx.doi.org/10.1007/s10147-023-02360-8
work_keys_str_mv AT mishimasaori japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT naitoyoichi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT akagikiwamu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT hayashinaomi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT hirasawaakira japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT hishikitomoro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT igarashiataru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT ikedamasafumi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT kadowakishigenori japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT kajiyamahiroaki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT katomotohiro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT kenmotsuhirotsugu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT koderayasuhiro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT kominekeigo japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT koyamatakafumi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT maedaosamu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT miyachimitsuru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT nishiharahiroshi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT nishiyamahiroyuki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT ohgashouichi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT okamotowataru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT okieiji japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT onoshigeru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT sanadamasashi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT sekineikuo japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT takanotadao japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT taokayoko japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT terashimakeita japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT tsuchiharakatsuya japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT yatabeyasushi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT yoshinotakayuki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors
AT babaeishi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors